LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced it has received regulatory approval from the Korean Ministry of Health to market the Company’s leading prescription skincare line, the Obagi Medical Nu-Derm System™, as well as the Obagi Medical Nu-Derm Condition and Enhance System™ for use before and after popular aesthetic procedures including Botox injections and Laser resurfacing. Dongkook Pharmaceuticals, an established pharmaceuticals marketing and manufacturing company, will begin selling Obagi Medical products this week throughout South Korea under an existing exclusive agreement with the Company.
